[Form 4] Avidity Biosciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Avidity Biosciences, Inc. (RNA) Form 4 filing: Chief Program Officer Kathleen P. Gallagher reported a single open-market sale of company common stock executed on 06/17/2025. The sale, carried out under a previously established Rule 10b5-1 trading plan (adopted 06/12/2024), involved 911 shares at a price of $30.24 per share.

Following the transaction, Gallagher’s direct holding stands at 50,392 shares. The filing was signed on 06/18/2025 and indicates that the Form 4 was filed by one reporting person only. No derivative transactions or additional equity awards were disclosed.

The relatively small share quantity and continued sizeable ownership suggest the transaction is routine in nature rather than signaling a material change in insider sentiment.

Insights

Securities Analyst

TL;DR: Small 911-share insider sale; routine, low impact.

The filing shows Gallagher disposed of only 911 shares (about a few trading-day volumes for RNA) at $30.24 via a pre-arranged 10b5-1 plan. Her remaining 50,392-share stake indicates continued exposure. No derivatives exercised, no new grants, and the position change is immaterial to the float. From a valuation or governance standpoint, I view the sale as neutral for investors.

Corporate Governance Expert

TL;DR: Pre-planned sale aligns with best-practice disclosure; neutral.

Execution under an established 10b5-1 plan minimizes concerns over information asymmetry. The officer remains well invested, supporting alignment with shareholder interests. No other insiders participated, and no policy breaches are evident. Hence, governance impact is nil, and market reaction should be muted.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gallagher Kathleen P.

(Last) (First) (Middle)

C/O AVIDITY BIOSCIENCES, INC.

10578 SCIENCE CENTER DR., SUITE 125

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Avidity Biosciences, Inc. [ RNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Program Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2025		S(1)		911	D	$30.24	50,392	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024.

Remarks:

	/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Avidity Biosciences (RNA) shares did Kathleen P. Gallagher sell?

911 common shares were sold.

At what price were the RNA shares sold according to the Form 4?

The shares were sold at $30.24 per share.

When was the insider transaction executed and filed?

Executed on 06/17/2025; Form 4 signed and filed on 06/18/2025.

How many RNA shares does the officer own after the sale?

Kathleen P. Gallagher now directly holds 50,392 shares.

Was the sale made under a Rule 10b5-1 trading plan?

Yes. The transaction was executed under a 10b5-1 plan adopted on 06/12/2024.